Emerging
Jun 18, 20261
61%
FDA Panel Reviews Moderna's mRNA Flu Vaccine mFlusiva for Older Adults
The FDA advisory panel is evaluating Moderna's mFlusiva, a new mRNA-based flu vaccine for people 50 and older. The vaccine reduced flu cases by 27 percent in clinical trials, though its approval process earlier faced an unusual dispute with FDA officials over study design comparisons.
Quick Facts
Who
Moderna
What
FDA advisory committee meeting to review mRNA flu vaccine
When
Thursday (meeting date)
Where
Washington
- FDA advisory committee meeting to review mRNA flu vaccine
- Moderna seeking approval for mFlusiva vaccine
- Clinical trial showing 27% reduction in flu cases
- Earlier FDA blocking of application
- Moderna challenging FDA decision
U.S. health advisers convened on Thursday to evaluate mFlusiva, a first-of-its-kind influenza vaccine developed by Moderna using mRNA technology—the same technology that proved instrumental in combating the COVID-19 pandemic. The FDA advisory committee meeting represents a critical step toward potential approval ahead of the winter flu season. Moderna is seeking full approval for use in people aged 50 to 64, along with authorization for those 65 and older pending additional testing.
Influenza claims tens of thousands of American lives annually, with older adults facing particular vulnerability. While several flu vaccines already exist in the United States, including three formulations specifically recommended for those 65 and older, mRNA-based vaccines offer a significant manufacturing advantage: they can be produced more rapidly than conventional vaccines. This speed could prove valuable if the highly mutable flu virus evolves in ways requiring prompt development of matching vaccines.
Moderna's clinical data demonstrated promising results. A study involving 40,000 people aged 50 and older showed that the mRNA vaccine reduced flu cases by approximately 27 percent compared to a standard-dose vaccine brand. The FDA's pre-meeting review of this data was favorable, with officials reporting no safety concerns. A smaller secondary study found that Moderna's vaccine generated flu-fighting antibodies at levels similar to a high-dose senior vaccine formulation. However, the FDA noted that the vaccine currently lacks data on very frail older adults and those with compromised immune systems.
The approval process has not proceeded without controversy. Earlier in 2026, Dr. Vinay Prasad, then a top FDA vaccine official, blocked Moderna's application, arguing the company should have compared its shot against a high-dose flu vaccine recommended for seniors rather than a standard-dose brand—a decision reflecting heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr. Moderna contested this decision, pointing out that FDA staff had previously approved the main study's design and citing the separate high-dose comparison study. Within days of the dispute, the FDA accepted Moderna's application, allowing the advisory committee review to proceed.
Why This Matters
mFlusiva represents a technological breakthrough in flu vaccination that could fundamentally change how rapidly flu vaccines are produced and deployed. For older adults—who face the highest mortality risk from influenza annually—this new mRNA option offers potentially faster development cycles if flu viruses evolve unexpectedly, directly addressing pandemic preparedness. The regulatory controversy also signals broader scrutiny over vaccine approval standards under the current administration, making this decision consequential for future vaccine development timelines and industry confidence.
Timeline & Sources
Jun 18, 2026
WireFDA advisory committee meeting to review mFlusiva vaccine